|
| |
| | Hospital Practice: New Perspectives on Pneumococcal Meningitis |
 | | Guidelines for the diagnosis and therapy of patients with suspected and confirmed pneumococcal meningitis will continue to evolve in response to changing resistance patterns, the availability of new antibiotics and vaccines, and a better understanding of the role of adjunctive therapy. | | | Bench research has helped to elucidate the pathogenesis and pathophysiology of pneumococcal meningitis and may lead to new therapeutic strategies. | | | While research efforts have enhanced our understanding of the pathogenesis and pathophysiology of this disease, the resultant therapeutic implications have yet to be fully realized. |
|
http://www.hosppract.com/issues/2001/02/cearon.htm
(2758 words)
|
|
| |
| | NIH Guide: MECHANISMS OF AIDS PATHOGENESIS |
| | This RFA is intended to foster applications for integrated, multi-disciplinary pathogenesis research linking in vitro studies to in vivo disease and focusing specifically on these three scientific areas. | | | For example, the applicant may be able to coordinate SIV pathogenesis projects with DAIDS-supported vaccine or drug development studies in macaques. | | | In vivo research includes studies of human clinical or epidemiologic cohorts, of animal models, or of appropriate specimens from humans or animals. |
|
http://grants.nih.gov/Grants/guide/rfa-files/RFA-AI-94-018.html
(3372 words)
|
|
| |
| | Second International AIDS Society Conference on HIV Pathogenesis and Treatment |
| | The message: expanding antiretroviral drug access in the developing world is a moral, ethical, and economic imperative following 20 years of advances in the study and treatment of HIV disease in the United States and Europe. | | | Brian Conway, MD, comments and provides relevant illustrations to an expert debate on the relative importance of evidence-based and principle-driven approaches to the optimal management of HIV infection. | | | Mauro Schechter, MD, PhD, comments on present and planned treatment access initiatives in the developing world vis-à-vis the Brazilian experience. |
|
http://www.medscape.com/viewprogram/2536
(1354 words)
|
|
| |
| | The Seattle Times: Business & Technology: Chiron trims Seattle operations; Pathogenesis work shifts to California |
| | Bruce Montgomery, chief executive of Corus Pharma and the former head of research and development at Pathogenesis, said the newly laid-off drug developers should find strong demand for their skills. | | | Some workers do clinical research, while others develop chemical processes to build up drug manufacturing or work in information technology. | | | At the time it was acquired, Pathogenesis was not profitable, but growing, and had some anti-microbial drugs showing promise in animal testing. |
|
http://seattletimes.nwsource.com/html/businesstechnology/2001920950_chiron06.html
(467 words)
|
|
| |
| | PathoGenesis Corp. Gains U.K. Approval of TOBI |
| | The other E.U. countries will be asked to approve the inhaled drug through a mutual recognition process. | | | Terms and conditions, including restrictions on redistribution, apply. | | | Seattle-based PathoGenesis Corp. develops and commercializes drugs to treat chronic infectious diseases -- particularly serious lung infections, including those common in cystic fibrosis, bronchiectasis and ventilator patients. |
|
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/12-15-1999/0001096892&EDATE=
(409 words)
|
|
| |
| | IAS Conference - Paris 2003 |
| | IAS 2005 aims to bring together participants from around the world by providing an environment for researchers and clinicians to address current issues in HIV research, prevention and treatment. | | | Following the Opening Session, delegates and accompanying persons will be invited to a unique evening event to enjoy and remember | | | The Scientific Programme of the 2nd IAS Conference on HIV Pathogenesis and Treatment is planned to provide new insights into HIV disease that can lead to new research directions, help speed translational research and move advances into clinical practice. |
|
http://www.ias2003.org/start.aspx
(392 words)
|
|
| |
| | The 2nd IAS Conference on HIV Pathogenesis and Treatment - Kaisernetwork.org |
| | Main Plenary: "HIV entry: insights into viral tropism, pathogenesis, and antiviral therapy"; "Mechanisms and management of metabolic complications associated with highly active antiretroviral therapy." | | | Main Plenary: "Challenges and lessons learned in implementing antiretroviral therapy in the developing world"; "Host/virus mechanisms in the molecular pathogenesis of HIV." | | | The Scientific Programme of the 2nd IAS Conference on HIV Pathogenesis and Treatment will provide new insights into HIV that can lead to new research directions, help speed translational research and move advances into clinical practice. |
|
http://www.kaisernetwork.org/health_cast/hcast_index.cfm?display=detail&hc=890
(357 words)
|
|
| |
| | Medmicro Chapter 45 |
| | Even at the earliest stage of pathogenesis (implantation), certain variables may influence the final outcome of the infection. | | | Pathogenesis is the process by which an infection leads to disease. | | | Pathogenesis is the process by which virus infection leads to disease. |
|
http://gsbs.utmb.edu/microbook/ch045.htm
(3478 words)
|
|
| |
| | Lipton v. Pathogenesis Corp. |
| | The IMS data was available to the investment analysts who followed PathoGenesis and was available to anyone who subscribed directly with IMS or through an intermediary, such as ProMetrics. | | | PathoGenesis Corporation ("PathoGenesis" or "the Company"), founded in 1991, is a pharmaceutical company that develops and markets medicines to treat chronic infectious diseases. | | | As an inhaled medicine, TOBI delivers tobramycin in greater concentrations than is possible through intravenous treatment. |
|
http://www.law.com/regionals/ca/opinions/mar/0035268.shtml
(4421 words)
|
|
| |
| | Pathogenesis |
| | Thus, increasing our knowledge of these many processes and steps (collectively called pathogenesis) is essential to the development of more effective prevention and treatment methods. | | | Though this project targets the pathogenesis of breast cancer, the strategies developed here will find broad application to other cancers and to breast cancer therapy. | | | This provides a new class of molecules to study the process of angiogenesis in human breast cancer. |
|
http://www.ucop.edu/srphome/bcrp/compendium/1996/patho.html
(9230 words)
|
|
| |
| | Molecular Pathogenesis Program |
| | The program faculty's research interests span a wide range of questions regarding host-microbe interactions and related topics in pathogenesis, which allows the entering trainee considerable breadth of choice of experimental systems, approaches and research topics. | | | The Microbiology and Molecular Pathogenesis Program (M2P2) provides graduate students and postdoctoral fellows with first-rate training to prepare them for careers in research as competitive, independent investigators. | | | Our research areas include bacteria, fungi, parasites, microbe-host interactions and microbe-microbe interactions. |
|
http://www.dartmouth.edu/~molpath
(158 words)
|
|
| |
| | Molecular Pathogenesis |
| | Immunologists in the MP program also study medically relevant problems such as the mechanisms of HIV pathogenesis, allergic disease, autoimmunity, and lymphomagenesis. | | | The MP program's immunology laboratories study diverse problems in the areas of lymphocyte signal transduction, immunological synapse formation, leukocyte trafficking, VDJ recombination, and innate immune responses. | | | Our goals are to identify human host factors required for HIV replication and pathogenesis and to engineer mice permissive for HIV infection and replication. |
|
http://saturn.med.nyu.edu/research/mp
(2130 words)
|
|
| |
| | Amazon.ca: Books: Bacterial Pathogenesis: A Molecular Approach |
| | I would have appreciated a more clinical approach to pathogenicity. | | | Look for books like Bacterial Pathogenesis: A Molecular Approach by subject: | | | Buy Bacterial Pathogenesis: A Molecular Approach with Histotechnology: A Self Instructional Text today! |
|
http://www.amazon.ca/exec/obidos/ASIN/155581171X
(306 words)
|
|
| |
| | The Body: The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment |
| | The Body: The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment | | | The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. | | | The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment |
|
http://www.thebody.com/confs/ias2003/ias2003.html
(535 words)
|
|
| |
| | Molecular Microbial Pathogenesis |
| | Microbial Pathogenesis is the study of the molecular mechanisms used by microbes to cause disease in humans and animals. | | | Understanding how microbes cause disease is often the first step toward the development of new therapeutic approaches. | | | Opportunities for research training in Microbial Pathogenesis at VCU are provided by an interactive group of well funded investigators from several departments including Microbiology and Immunology. |
|
http://www.vcu.edu/micro/micpathogen.htm
(474 words)
|
|
| |
| | Search Results for pathogenesis - Encyclopædia Britannica |
| | Pathogenesis is the stage of disease in which the pathogen is in intimate association with living host tissue. | | | Includes notes on its neurologic manifestations, pathogenesis, and treatments. | | | Covers pathogenesis, cytogenetics, mapping, diagnosis, and clinical management. |
|
http://www.britannica.com/search?query=pathogenesis&submit=Find&source=MWTEXT
(393 words)
|
|
| |
| | Bacterial Pathogenesis |
| | Pathogenesis is a multi-factorial process which depends on the immune status of the host, the nature of the species or strain (virulence factors) and the number of organisms in the initial exposure. | | | A limited number of bacterial species are responsible for the majority of infectious diseases in healthy individuals. | | | Shiga toxins (chromosomally encoded) are involved in the pathogenesis of shigellosis, whilst shiga-like toxins (phage encoded) are primarily produced by enterohemorraghic E. |
|
http://pathmicro.med.sc.edu/fox/bact-path.htm
(2143 words)
|
|
| |
| | Deep Vein Thrombosis, epidemiology, pathogenesis and risk factors MEDSTUDENTS- INTERNAL MEDICINE |
| | Three mechanisms are involved in the pathogenesis of venous thrombosis, they are: venous stasis, injury to the venous wall, and hypercoagulable states. | | | Deep vein thrombosis (DVT) is a common but elusive illness that can result in suffering and death if not recognized and treated effectively.Death can occur when the venous thrombi break off and form pulmonary emboli, which pass to and obstruct the arteries of the lung. | | | Venous stasis predisposes the patients to venous thrombosis mainly by impairing the clearance of activated coagulation factors from the local where thrombus is formed, and vascular damage contributes to the genesis of venous thrombosis through either direct trauma, or activation of endothelial cells by cytokines. |
|
http://www.medstudents.com.br/medint/medint4.htm
(613 words)
|
|
| |
| | Laboratory of Human Bacterial Pathogenesis, NIAID, NIH |
| | The Laboratory of Human Bacterial Pathogenesis (LHBP) studies the molecular basis of human bacterial pathogenesis in its broadest sense. | | | Research projects currently focus on the pathogenic Borrelia species, Yersinia pestis, group A Streptococcus, Mycobacterium tuberculosis, and Staphylococcus epidermidis. |
|
http://www.niaid.nih.gov/dir/labs/lhbp.htm
(146 words)
|
|
| |
| | Mechanisms of Bacterial Pathogenesis |
| | These "N-methylphenylalanine pili" have been established as virulence determinants in pathogenesis of Pseudomonas aeruginosa lung infection in cystic fibrosis patients. | | | These type of fimbriae occur in Neisseria gonorrhoeae and their receptor is thought to be an oligosaccharide. | | | Heterotrophic bacteria, in general, produce a wide variety of extracellular enzymes including proteases, lipases, glycohydrolases, nucleases, etc., which are not clearly shown to have a direct role in invasion or pathogenesis. |
|
http://textbookofbacteriology.net/pathogenesis.html
(6644 words)
|
|
| |
| | Technical: Pathology CDC Hantaviruses |
| | However, the pathogenesis of HPS is complex, and a myocardial depressant may contribute significantly to the mortality of this disease. | | | It is unclear how the shock syndrome relates to factors such as viral distribution and immunologic and pharmacological mediators of capillary permeability. | | | Functional impairment of vascular endothelium is central to the pathogenesis of HPS. |
|
http://www.cdc.gov/ncidod/diseases/hanta/hps/noframes/phys/patho.htm
(261 words)
|
|
| |
| | CIDRAP >> Tularemia: Current, comprehensive information on pathogenesis, microbiology, epidemiology, diagnosis, ... |
| | Virulence factors that contribute to pathogenesis of F tularensis have not been well defined and further studies are needed. | | | Tularemia: Current, comprehensive information on pathogenesis, microbiology, epidemiology, diagnosis, treatment, and prophylaxis | | | CIDRAP >> Tularemia: Current, comprehensive information on pathogenesis, microbiology, epidemiology, diagnosis, treatment, and prophylaxis |
|
http://www.cidrap.umn.edu/cidrap/content/bt/tularemia/biofacts/tularemiafactsheet.html
(5971 words)
|
|
| |
| | tab001tgf: Comparison of disease pathogenesis of Ebola virus infection in animal models and humans |
| | Comparison of disease pathogenesis of Ebola virus infection in animal models and humans | | | (2003) Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. | | | tab001tgf: Comparison of disease pathogenesis of Ebola virus infection in animal models and humans |
|
http://www-ermm.cbcu.cam.ac.uk/04008324h.htm
(824 words)
|
|
| |
| | Workplan of the Pathogenesis and Applied Genomics Committee. The UNICEF-UNDP-World Bank-WHO Special Programme for ... |
| | The Committee also supports research activities in priority areas identified for promoting rapid applications of genomics in the development of new tools for diagnosis and treatment of tropical diseases. | | | The Pathogenesis and Applied Genomics Committee promotes novel approaches that take advantage of recent advances in molecular biology, immunology, gene technology and genomic structure to elucidate important host-parasite/virus relationships. | | | The Pathogenesis and Applied Genomics Committee, a component of the Steering Committee on Basic and Strategic Research (STR), promotes application of post genome activities in research on the pathogenesis of African trypanosomiasis, Chagas disease, dengue fever, lymphatic filariasis, leishmaniasis, leprosy, malaria, onchocerciasis, schistosomiasis, and tuberculosis. |
|
http://www.who.int/tdr/grants/workplans/pathogen.htm
(429 words)
|
|
| |
| | Elsevier Author Gateway |
| | Microbial Pathogenesis publishes original contributions, mini-reviews, and notes on molecular and cellular mechanisms in infectious disease. |
|
http://authors.elsevier.com/JournalDetail.html?PubID=622915&Precis=DESC
(52 words)
|
|
| |
| | PATHOGENESIS CORPORATION - Legal Case Documents |
| | PGNS is, essentially, a one-product company entirely dependent upon the success of its formulation of the antibiotic Tobramycin ("TOBI"), an inhaled antibiotic used to treat cystic fibrosis. | | | I. This is a class action brought on behalf of all persons, other than defendants and affiliated persons as described below (the "Class"), who purchased or otherwise acquired the common stock of PathoGenesis Corporation ("PGNS") between January 25, 1999 and March 22, 1999 (the "Class Period"), alleging violations of the federal securities laws. | | | Cnsl may file one JSR for all cases |
|
http://www.legalcasedocs.com/120/246/258.html
(836 words)
|
|
| |
| | Pseudomonas Genome Project and PseudoCAP |
| | aeruginosa strain PAO1 was determined in a collaboration among the Cystic Fibrosis Foundation, the University of Washington Genome Center and PathoGenesis Corporation. | | | Genome annotation was carried out by PathoGenesis scientists and by scientists in the Pseudomonas aeruginosa Community Annotation Project (PseudoCAP). |
|
http://www.pseudomonas.com
(358 words)
|
|
|
